Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy / Riham M Abdelgalil, Yomna M Elmorshedy, Kadria A Elkhodairy, Mohamed Teleb, Adnan A Bekhit, Sherine N Khattab, Ahmed O Elzoghby
Colorectal cancer (CRC) is one of the most devastating diseases worldwide. Immunotherapeutic agents for CRC treatment have shown limited efficacy due to the immunosuppressive tumor microenvironment (TME). In this context, various types of nanoparticles (NPs) have been used to reverse the immunosuppressive TME, potentiate the effect of immunotherapeutic agents and reduce their systemic side effects. Many advantages could be offered by NPs, related to drug-loading efficiency, particle size and others that can potentially aid the delivery of immunotherapeutic agents. The recent research on how nano-based immunotherapy can remodel the immunosuppressive TME of CRC and hence boost the antitumor immune response, as well as the challenges that face clinical translation of NPs and future perspectives, are summarized in this review article. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdelgalil, Riham M [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Colorectal cancer |
|---|
| Umfang: |
1 Online-Ressource (25 p) |
|---|
| doi: |
10.2217/nnm-2022-0214 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011095970 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011095970 | ||
| 003 | DE-627 | ||
| 005 | 20230713210643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0214 |2 doi | |
| 035 | |a (DE-627)KFL011095970 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2022-0214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Abdelgalil, Riham M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy |c Riham M Abdelgalil, Yomna M Elmorshedy, Kadria A Elkhodairy, Mohamed Teleb, Adnan A Bekhit, Sherine N Khattab, Ahmed O Elzoghby |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (25 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Colorectal cancer (CRC) is one of the most devastating diseases worldwide. Immunotherapeutic agents for CRC treatment have shown limited efficacy due to the immunosuppressive tumor microenvironment (TME). In this context, various types of nanoparticles (NPs) have been used to reverse the immunosuppressive TME, potentiate the effect of immunotherapeutic agents and reduce their systemic side effects. Many advantages could be offered by NPs, related to drug-loading efficiency, particle size and others that can potentially aid the delivery of immunotherapeutic agents. The recent research on how nano-based immunotherapy can remodel the immunosuppressive TME of CRC and hence boost the antitumor immune response, as well as the challenges that face clinical translation of NPs and future perspectives, are summarized in this review article. Graphical abstract | ||
| 653 | |a colorectal cancer | ||
| 653 | |a immunotherapy | ||
| 653 | |a nanocarriers | ||
| 653 | |a nanomedicine | ||
| 653 | |a theranostics | ||
| 700 | 1 | |a Elmorshedy, Yomna M |e verfasserin |4 aut | |
| 700 | 1 | |a Elkhodairy, Kadria A |e verfasserin |4 aut | |
| 700 | 1 | |a Teleb, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Bekhit, Adnan A |e verfasserin |4 aut | |
| 700 | 1 | |a Khattab, Sherine N |e verfasserin |4 aut | |
| 700 | 1 | |a Elzoghby, Ahmed O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2022-0214 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||